CAR T Cancer Treatment Is Revolutionary

CAR T Cancer Treatment Is Revolutionary
AP Photo/Gregory Bull

More than 7 years have passed since the regression of advanced lymphoma was first reported in a patient who had undergone the infusion of T cells engineered to express a chimeric antigen receptor (CAR) targeting the CD19 antigen expressed on the surface of both normal and malignant B cells.1 Subsequent trials of CD19-targeted CAR T-cell therapy showed a complete response in some patients with relapsed or chemotherapy-refractory hematologic cancers for which there were no effective therapies.2-5

Read Full Article »
Comment
Show comments Hide Comments

Related Articles